Nisitha Jayatilleke

Sydney, NSW 2031, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Correction: Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.

Correction: Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 11, 2026

Combined inhibition of FACT and BET disrupts transcription to suppress tumor growth in mouse models of diffuse midline glioma.

Combined inhibition of FACT and BET disrupts transcription to suppress tumor growth in mouse models of diffuse midline glioma.

Journal: Science translational medicine

Published: January 14, 2026

Surface Proteomic Analysis Reveals the Presence of Noncanonical Cell Membrane Endoplasmic Reticulum Chaperones in High-Grade Gliomas.

Surface Proteomic Analysis Reveals the Presence of Noncanonical Cell Membrane Endoplasmic Reticulum Chaperones in High-Grade Gliomas.

Journal: Journal of proteome research

Published: November 25, 2025

Immune-deficient MISTRG mice support expansion of leukaemia-initiating cells in xenograft models of paediatric acute myeloid leukaemia.

Immune-deficient MISTRG mice support expansion of leukaemia-initiating cells in xenograft models of paediatric acute myeloid leukaemia.

Journal: British journal of haematology

Published: September 26, 2024

The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis.

The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis.

Journal: Nature communications

Published: April 05, 2023

MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression.

MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression.

Journal: Oncogene

Published: November 17, 2022

NONO enhances mRNA processing of super-enhancer-associated GATA2 and HAND2 genes in neuroblastoma.

NONO enhances mRNA processing of super-enhancer-associated GATA2 and HAND2 genes in neuroblastoma.

Journal: EMBO reports

Published: March 04, 2022

Development of siRNA-Loaded Lipid Nanoparticles Targeting Long Non-Coding RNA LINC01257 as a Novel and Safe Therapeutic Approach for t(8;21) Pediatric Acute Myeloid Leukemia.

Development of siRNA-Loaded Lipid Nanoparticles Targeting Long Non-Coding RNA LINC01257 as a Novel and Safe Therapeutic Approach for t(8;21) Pediatric Acute Myeloid Leukemia.

Journal: Pharmaceutics

Published: August 17, 2021

Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.

Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 03, 2020

JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma.

JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma.

Journal: Nature communications

Published: April 27, 2018

Contributions of specific causes of death to lost life expectancy in severe mental illness.

Contributions of specific causes of death to lost life expectancy in severe mental illness.

Journal: European psychiatry : the journal of the Association of European Psychiatrists

Published: November 21, 2016

Burden of disease due to cancer in England and Wales.

Burden of disease due to cancer in England and Wales.

Journal: Journal of public health (Oxford, England)

Published: December 06, 2011

Showing 1-12 of 12

Last Updated: 09/26/2026